All In Biotech

Drug Trial Radar · NCT07045909

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

A Phase 2, Open-label, Multicenter Multi-cohort Study to Evaluate the Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Mar 31, 2028

Study completion Mar 31, 2030

Sponsor

Lead sponsor
PETHEMA FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if anitocabtagene autoleucel following induction therapy works to treat adult participants with newly diagnosed multiple myeloma. The main objectives of this clinical trial are: * To determine the incidence and severity of all adverse events (AEs). * To determine the proportion of patients achieving undetectable minimal residual disease (uMRD) negative-CR rate (minimum 10 to -5) at 12 months (+/- 3 months) after enrollment. Participants will receive induction therapy with a quadruplet regimen including a proteasome inhibitor (Bortezomib \[V\]), immunomodulatory drug (Lenalidomide \[R\]), dexamethasone \[d\] and anti-CD38 monoclonal antibody (Daratumumab \[D\] or Isatuximab \[Isa\]) followed by anitocabtagene autoleucel. Participants in Cohorts A and B will receive lenalidomide maintenance therapy following infusion with anitocabtagene autoleucel.

Conditions

  • De Novo Multiple Myeloma
  • Anitocabtagene Autoleucel

Interventions

  • DaratumumabDrug

    Daratumumab will be administered by subcutaneous (SC) injection.

  • IsatuximabDrug

    Isatuximab will be administered IV.

  • BortezomibDrug

    Bortezomib dose will be calculated using the patient's actual body surface area at baseline and will be administered by SC injection.

  • LenalidomideDrug

    Lenalidomide will be administered by oral route (all cohorts at induction, and cohorts A and B at maintenance).

  • CyclophosphamideDrug

    As part of lymphodepleting therapy before CAR-T manufacture, administered IV.

  • FludarabineDrug

    As part of lymphodepleting therapy before CAR-T manufacture, administered IV

  • Anitocabtagene AutoleucelDrug

    Single infusion IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of all adverse events (AEs)Time frame: 3 years
  2. Undetectable minimal residual disease (uMRD) negative-CR rate (minimum 10-5) at 12 months (+/- 3 months) after enrollment.Time frame: 12 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Germans Trias i Pujol (ICO BADALONA)

    Badalona, Spain · Recruiting

  • H. Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • H. 12 de Octubre

    Madrid, Spain · Recruiting

  • H. Ramón y Cajal

    Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Spain · Recruiting

  • Hospital Clinico Universitario Salamanca

    Salamanca, Spain · Recruiting

  • H. Marqués de Valdecilla

    Santander, Spain · Recruiting

  • C H Santiago de Compostela

    Santiago de Compostela, Spain · Recruiting

  • Complejo Hosp. Regional Virgen del Rocío

    Seville, Spain · Recruiting

  • Hospital Universitario y Politécnico La Fe de Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.